0.13 ? 0.0 (0.00%)
Volume: 0 @- ET
Bid Ask Day's Range
0.125 0.16 - - -
TSX:ALT Detailed Quote
Recent ALT News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/26/2025 11:30:26 AM
- Altimmune Shares Slide 37% Despite Hitting Key MASH Trial Goals • IH Market News • 06/26/2025 11:18:23 AM
- Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH • GlobeNewswire Inc. • 06/26/2025 11:00:00 AM
- Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26 • GlobeNewswire Inc. • 06/25/2025 11:12:07 PM
- Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific Sessions • GlobeNewswire Inc. • 06/13/2025 11:30:00 AM
- Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) • GlobeNewswire Inc. • 05/19/2025 11:30:00 AM
- Altimmune to Participate at Two Upcoming Investor Conferences • GlobeNewswire Inc. • 05/14/2025 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2025 08:55:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2025 11:04:35 AM
- Altimmune Announces First Quarter 2025 Financial Results and Business Update • GlobeNewswire Inc. • 05/13/2025 11:00:00 AM
- Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital • GlobeNewswire Inc. • 05/13/2025 11:00:00 AM
- Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™ • GlobeNewswire Inc. • 05/08/2025 11:30:00 AM
- Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 • GlobeNewswire Inc. • 05/06/2025 11:30:00 AM
- Altimmune to Present at Upcoming EASL International Liver Congress™ 2025 • GlobeNewswire Inc. • 05/01/2025 11:30:00 AM
- Altimmune to Participate in the Citizens Life Sciences Conference • GlobeNewswire Inc. • 04/30/2025 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2025 08:15:22 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/14/2025 04:15:11 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2025 08:03:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2025 08:05:11 PM
- Altimmune to Host Virtual R&D Day on March 13, 2025 • GlobeNewswire Inc. • 03/06/2025 12:30:00 PM
- Altimmune to Participate in the Leerink Global Healthcare Conference • GlobeNewswire Inc. • 03/03/2025 12:30:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/27/2025 09:49:48 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/27/2025 09:36:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2025 12:05:35 PM
- Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 02/27/2025 12:00:00 PM
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs • CLDI • Jul 7, 2025 9:00 AM
VAYK Discloses More Insider Buying Approaching 15 Million • VAYK • Jul 2, 2025 10:37 AM
Patented, Groundbreaking Blockchain for Public Companies 'BlackStar Digital Trading PlatformTM' can Facilitate U.S. Registered Securities to Trade on Blockchain Without Tokens. • BEGI • Jul 1, 2025 12:54 PM
UC Asset (UCASU) Public Offering's Acquisition Target Reported Better Results • UCASU • Jul 1, 2025 9:15 AM
One World Products, Inc. Appoints William Rowland as Chief Financial Officer • OWPC • Jul 1, 2025 9:14 AM
Envirotech Begins Delivery of Bumble Bee Electric School Bus Units with First Three Texas Orders • EVTV • Jul 1, 2025 9:01 AM